Recent Faculty Publications
Our neurological research frequently appears in leading academic journals and reflects a broad scope of interests.
- Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology. 2020
- Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J, Wolfe GI. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2020
- Barohn RJ, Gajewski B, Pasnoor M, Brown A, Herbelin LL, Kimminau KS, Mudaranthakam DP, Jawdat O, Dimachkie MM, Iyadurai S, Stino A, Kissel J, Pascuzzi R, Brannagan T, Wicklund M, Ahmed A, Walk D, Smith G, Quan D, Heitzman D, Tobon A, Ladha S, Wolfe G, Pul. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial. JAMA Neurol. 2020
- Minen MT, Wells RE, Gautreaux JR, Szperka CL, Rayhill M, Orlova Y, Metzler A, Halpern A, Monteith T, Rayhill ML. Responding to the Needs of Early Career Physicians and Fellows in Headache Medicine: Career Planning, Getting Involved, and Considerations in Building a Headache Center. Headache. 2020
- McPherson T, Aban I, Duda PW, Farzaneh-Far R, Wolfe GI, Kaminski HJ, Cutter G, Lee I. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study. Muscle Nerve. 2020
- Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020; 77(5)
- Wang, X, Covey TJ. Neurophysiological indices of the transfer of cognitive training gains to untrained tasks.. Neurobiology of Learning and Memory. 2020; 171
- Cudkowicz M, Chase MK, Coffey CS, Ecklund DJ, Thornell BJ, Lungu C, Mahoney K, Gutmann L, Shefner JM, Staley KJ, Bosch M, Foster E, Long JD, Bayman EO, Torner J, Yankey J, Peters R, Huff T, Conwit RA, Shinnar S, Patch D, Darras BT, Ellis A, Packer RJ, Mar. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurol. 2020
- Wasilewski A, Serventi J, Ibegbu C, Wychowski T, Burke J, Mohile N. Epilepsy education in gliomas: engaging patients and caregivers to improve care. Support Care Cancer. 2020; 28(3)
- Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? J Neurol Sci. 2020; 408
- Occhiogrosso J, Hemminger L, Burke J, Ibegbu C, Serventi J, Mohile N. Treatment-Related Decisions in Malignant Gliomas: A Feasibility Study. J Palliat Med. 2020; 23(2)
- Green JD, Barohn RJ, Bartoccion E, Benatar M, Blackmore D, Chaudhry V, Chopra M, Corse A, Dimachkie MM, Evoli A, Florence J, Freimer M, Howard JF, Jiwa T, Kaminski HJ, Kissel JT, Koopman WJ, Lipscomb B, Maestri M, Marino M, Massey JM, McVey A, Mezei MM, M. Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open. 2020; 10(9)
- Piehl F, Wolfe GI. Is the treatment of myasthenia gravis improving? Why not ask our patients? Neurology. 2020; 95(12)
- Lee I, Kuo HC, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Sussman J, Ströbel P, Oger J, Cea G, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF,. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020; 95(6)
- Ozel O, Vaughn CB, Eckert SP, Jakimovski D, Lizarraga AA, Weinstock-Guttman B. Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives.. Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives. Patient Relat Outcome Measures. 2019; 10
- Borrero-Mejias C, Starling AJ, Burch R, Loder E, Rayhill ML. Eleven Things Not to Say to Your Female Colleagues. Headache. 2019; 59(10)
- Primma Eckert S, Weinstock-Guttman B. Diagnosis and Disease Monitoring: Advances in Clinical MRI for Multiple Sclerosis. Neurodiem.com. 2019
- Guttuso T, Andrzejewski KL, Lichter DG, Andersen JK, Guttuso, Jr. TJ. Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J Neurol Sci. 2019; 402
- Covey TJ, Shucard, DW, Meynadasy, M, Mang, T, Arany, PR. Photobiomodulation as a potential therapeutic strategy for improving cognitive and functional outcomes in traumatic brain injury. Elsevier. 2019
- Weinstock A, Agarwal N, Farooq O, Cheema Z, Hamilton D, Parrish J. Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study. J Child Neurol. 2019; 34(8)
